title: A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
abstract: In order to assess the effect of delaying G-CSF administration after autologous peripheral blood progenitor cell (PBPC) transplantation on the duration of neutropenia, 87 patients were randomized to receive G-CSF 5 microg/kg/day starting on day +1 (n = 45) or +5 (n = 42) following PBPC transplantation, until recovery of the neutrophils. The duration of neutropenia (<0.5 x 10(9)/l) was shorter in the day +1 group (7 vs 8 days; P = 0.02), especially in patients receiving melphalan 200 mg/m(2) and CD34(+) cell doses >3.0 x 10(6)/kg. These patients had a later onset of neutropenia after transplant. There were no differences in time to neutrophil and platelet engraftment, or in the incidence of fever and documentation of infection. Although the duration of antibiotic therapy (7 vs 10.5 days; P = 0.01) and time to hospital discharge (13 vs 15 days; P = 0.02) were shorter in the day +1 group, these differences could not be predicted by the day of G-CSF initiation in multivariate analysis. Starting G-CSF on day +1 does not result in faster neutrophil engraftment but in later onset and consequently, slightly shorter duration of neutropenia in patients who receive melphalan 200 mg/m(2) and CD34(+) cell doses >3.0 x 10(6)/kg.
authors.affiliation: University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
authors.forename: A M
authors.initials: AM
authors.lastname: de Azevedo
authors.forename: M
authors.initials: M
authors.lastname: Nucci
authors.forename: A
authors.initials: A
authors.lastname: Maiolino
authors.forename: A C
authors.initials: AC
authors.lastname: Vigorito
authors.forename: B P
authors.initials: BP
authors.lastname: Simões
authors.forename: F J P
authors.initials: FJ
authors.lastname: Aranha
authors.forename: D G
authors.initials: DG
authors.lastname: Tabak
authors.forename: J
authors.initials: J
authors.lastname: Voltarelli
authors.forename: C A
authors.initials: CA
authors.lastname: de Souza
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000209:etiology / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D019337:Hematologic Neoplasms / Q000150:complications / Q000628:therapy; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000517:prevention & control; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D011446:Prospective Studies; D014182:Transplantation, Autologous / Q000009:adverse effects / Q000379:methods; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor